You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 119 No. 12, December 1983 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (53)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Changes in Plasma Cholesterol and Triglyceride Levels After Treatment With Oral Isotretinoin

A Prospective Study

Loren A. Zech, MD; Earl G. Gross, MD; Gary L. Peck, MD; H. Bryan Brewer, MD

Arch Dermatol. 1983;119(12):987-993.


Abstract

• Twenty men with nodulocystic acne were treated with oral isotretinoin (13-cis-retinoic acid) for four months. Plasma lipids and lipoprotein determinations were obtained before and during treatment to quantitate the effects of oral isotretinoin on lipid metabolism. Maximum isotretinoin-induced elevations in plasma triglyceride and cholesterol levels were 67% and 16%, respectively. Additional maximal changes included very-low-density lipoprotein cholesterol increases of 56%, low-density lipoprotein cholesterol increases of 22%, and high-density lipoprotein decreases of 10% from pretreatment values. Chronic increases in plasma cholesterol levels, increases in low-density lipoprotein cholesterol levels, and decreases in high-density lipoprotein cholesterol levels may predispose subjects to premature atherosclerosis. Because of the potential for unmasking an occult lipid or lipoprotein disorder, the plasma lipid and lipoprotein profiles of subjects receiving isotretinoin should be carefully monitored.

(Arch Dermatol 1983;119:987-993)



Author Affiliations

From the Molecular Disease Branch, National Heart, Lung, and Blood Institute (Drs Zech and Brewer) and the Dermatology Branch, National Cancer Institute (Drs Gross and Peck), National Institutes of Health, Bethesda, Md.


Footnotes

Accepted for publication June 3, 1983.

Reprint requests to Bldg 10, Room 7N117, National Institutes of Health, Bethesda, MD 20902 (Dr Zech).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines
Corbetta et al.
Eur J Endocrinol 2006;154:83-86.
ABSTRACT | FULL TEXT  

High Risk for Hyperlipidemia and the Metabolic Syndrome after an Episode of Hypertriglyceridemia during 13-cis Retinoic Acid Therapy for Acne: A Pharmacogenetic Study
Rodondi et al.
ANN INTERN MED 2002;136:582-589.
ABSTRACT | FULL TEXT  

An Observational Study of Isotretinoin Recipients Treated for Acne in a Health Maintenance Organization
McElwee et al.
Arch Dermatol 1991;127:341-346.
ABSTRACT  

Side Effects and Long-term Toxicity of Synthetic Retinoids
Yob and Pochi
Arch Dermatol 1987;123:1375-1378.
ABSTRACT  

Pancreatitis Associated with Isotretinoin-lnduced Hypertriglyceridemia
FLYNN et al.
ANN INTERN MED 1987;107:63-63.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.